Provided by Tiger Trade Technology Pte. Ltd.

IMMUNEONCO-B

3.390
-0.085-2.45%
Volume:128.80K
Turnover:436.87K
Market Cap:1.45B
PE:-6.40
High:3.475
Open:3.475
Low:3.320
Close:3.475
52wk High:16.800
52wk Low:2.800
Shares:429.00M
HK Float Shares:418.00M
Volume Ratio:0.19
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.530
ROE:-29.87%
ROA:-13.80%
PB:1.58
PE(LYR):-6.40
PS:8.08

Loading ...

ImmuneOnco Executes HKD 1.29 Million Share Buyback, Trimming Free Float by 0.10%

Bulletin Express
·
Jun 09

IMMUNEONCO-B repurchases 0.06% of H-share float for HKD 0.83 million

Bulletin Express
·
Jun 08

IMMUNEONCO-B Executes Share Buyback, Spending HK$827,800

Stock News
·
Jun 08

ImmuneOnco Biopharmaceuticals (Shanghai) - to Repurchase H Shares in Open Market

THOMSON REUTERS
·
Jun 08

Asian Market Insights: ImmuneOnco Biopharmaceuticals (Shanghai) Among 3 Promising Penny Stocks

Simply Wall St.
·
Jun 08

IMMUNEONCO-B Shares Surge Over 7% on Positive Early Trial Data for SLE Drug Candidate

Stock News
·
Jun 05

ImmuneOnco Biopharmaceuticals Reports No Change in Share Capital for May 2026

Bulletin Express
·
Jun 03

Hong Kong Stock Surge: IMMUNEONCO-B Soars Over 7% on Positive IMM2510 Data for IO-Refractory Lung Cancer

Stock News
·
Jun 02

IMMUNEONCO-B AGM Endorses 2025 Financials, Reappoints Deloitte and Renews Dual Mandates

Bulletin Express
·
May 28

IMMUNEONCO-B (01541) Redeems HK$205 Million Shenwan Products and Subscribes to HK$212 Million Shenwan Hongyuan Wealth Management Products

Stock News
·
May 22

ImmuneOnco Biopharmaceuticals (Shanghai) Inc - to Subscribe for HK$212 Mln Shenwan Wealth Management Product on May 22, 2026

THOMSON REUTERS
·
May 22

ImmuneOnco Doses First Patient in IMM0306 Drug Trial; Shares Fall 3%

MT Newswires Live
·
May 20

IMMUNEONCO-B (01541) Achieves Milestone with First Patient Dosed in Phase II SLE Trial for IMM0306

Stock News
·
May 19

IMMUNEONCO-B Surges Over 6% in Late Trading as IND Application for IMM0306 in Primary Sjögren's Syndrome Gains Official Approval

Stock News
·
May 19

ImmuneOnco records stable share base in April 2026; public-float requirement fully met

Bulletin Express
·
May 07

ImmuneOnco Biopharmaceuticals announces annual general meeting notice

Reuters
·
Apr 30

ImmuneOnco Biopharmaceuticals收入倍增 2025年研发布局稳步扩张,全年亏损明显收窄

Bulletin Express
·
Apr 29

IMMUNEONCO-B Shares Climb Over 5% as Subsidiary Completes Patient Enrollment for IMC-003 Study

Stock News
·
Apr 22

IMMUNEONCO-B Soars Over 17% as Science Journal Validates CD47 Bispecific Antibody's Clinical Potential

Stock News
·
Apr 13

Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone

Stock Track
·
Mar 31